Having trouble accessing articles? Reset your cache.

Hua Phase III diabetes data make good on glucokinase but disappoint investors

Hua’s glucokinase activator notches a Phase III win for the long-pursued target

Hua’s announcement that glucokinase activator dorzagliatin met its endpoints in a Phase III diabetes study marks a watershed moment for a target whose disease-modifying potential was long stymied by the limitations of previous compounds. Yet the company’s stock dropped on the news, suggesting investors expected a more differentiated profile.

The Chinese biotech licensed dorzagliatin from Roche (SIX:ROG; OTCQX:RHHBY) in 2012. Hua Medicine Ltd. (HKEX:2552) is developing it as a monotherapy and in combination with five marketed diabetes treatments. Hua has one other asset, a mGluR5 allosteric modulator, in preclinical testing for Parkinson’s disease and depression.

Glucokinase activators operate by modulating a glucose sensor that controls key functions dysregulated in Type II diabetes, such as insulin and glucagon secretion by the pancreas, and glycogen storage

Read the full 1225 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE